Neratinib in early-stage breast cancer : clinical trial data
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 Suppl 12 |
---|---|
Enthalten in: |
Clinical advances in hematology & oncology : H&O - 18 Suppl 12(2020), 8 vom: 01. Aug., Seite 7-10 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
O'Regan, Ruth [VerfasserIn] |
---|
Themen: |
EC 2.7.10.1 |
---|
Anmerkungen: |
Date Completed 22.09.2021 Date Revised 22.09.2021 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM323988946 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM323988946 | ||
003 | DE-627 | ||
005 | 20231225185345.0 | ||
007 | tu | ||
008 | 231225s2020 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n1079.xml |
035 | |a (DE-627)NLM323988946 | ||
035 | |a (NLM)33843845 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a O'Regan, Ruth |e verfasserin |4 aut | |
245 | 1 | 0 | |a Neratinib in early-stage breast cancer |b clinical trial data |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 22.09.2021 | ||
500 | |a Date Revised 22.09.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Quinolines |2 NLM | |
650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a neratinib |2 NLM | |
650 | 7 | |a JJH94R3PWB |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Clinical advances in hematology & oncology : H&O |d 2003 |g 18 Suppl 12(2020), 8 vom: 01. Aug., Seite 7-10 |w (DE-627)NLM157777022 |x 1543-0790 |7 nnns |
773 | 1 | 8 | |g volume:18 Suppl 12 |g year:2020 |g number:8 |g day:01 |g month:08 |g pages:7-10 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 Suppl 12 |j 2020 |e 8 |b 01 |c 08 |h 7-10 |